Zura Bio Ltd — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Zura Bio (market cap ~$59M) reported Q3 2026 financials: cash of $187.7M (sufficient through end-2028), R&D expenses $19.5M (vs. $11.9M YoY), and net loss of $25.8M ($0.20/share). TibuSHIELD Phase 2 (HS) enrolled 247 participants, topline data due Q4 2026; TibuSURE Phase 2 (SSc) enrolled 91 participants, topline due H1 2027; NEXUS-PMR Phase 2 (PMR) FDA-cleared, initiation planned by year-end 2026. Tibulizumab is a bispecific antibody targeting IL-17 and BAFF. No material partnerships or financing events disclosed.
Why this rating
Company well-funded through key data milestones (3.2x annual burn). Three independent Phase 2 readouts imminent in large unmet-need markets (~$5–15B TAM). Near-term catalysts reduce execution risk. Moderate significance because outcome still uncertain.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.